摘要 |
The present invention provides diagnostic methods for predicting the effectiveness of treatment of an ovarian cancer patient with an IGF- IR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-IR kinase inhibitor, comprising assessing whether the tumor cells possess mutant K-RAS. The present invention thus provides a method of identifying patients with ovarian cancer who are most likely to benefit from treatment with an IGF- IR kinase inhibitor. Improved methods for treating cancer patients with IGF-IR kinase inhibitors that incorporate this methodology are also provided. The present invention also provides diagnostic methods for predicting the effectiveness of treatment of cancer patients with IGF-IR kinase inhibitors, based on a determination of the mutation status of the genes K-RAS, B-RAF, PTEN and PIK3CA, which can be used to identify tumor cell types that will be sensitive to IGF-IR kinase inhibitors, and also those that will be insensitive. |
申请人 |
OSI PHARMACEUTICALS, LLC;BUCK, ELIZABETH, A.;BARR, SHARON, M.;MIGLARESE, MARK, R. |
发明人 |
BUCK, ELIZABETH, A.;BARR, SHARON, M.;MIGLARESE, MARK, R. |